Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells

Toxicology Letters

Volumn 215, Issue 3, 2012, Pages 219-227

  Fuhrmeister, Jessica ^a   Tews, Martha ^a   Kromer, Andrea ^a   Moosmann, Bernd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

HMG CoA reductase; Mevalonate pathway; Myopathy; Oxidative stress; Selenoproteins; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EBSELEN; GLUTATHIONE PEROXIDASE 1; IONOPHORE; MEVALONIC ACID; SELENITE; SELENOPROTEIN; SODIUM SELENITE; TERT BUTYL HYDROPEROXIDE; UBIQUINONE;

ANIMAL CELL; ARTICLE; BIOAVAILABILITY; CELL DIFFERENTIATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; MOUSE; MUSCLE CELL; MYOBLAST; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; SKELETAL MUSCLE; STEADY STATE; TITRIMETRY;

ANIMALS; CELL LINE; CELL SURVIVAL; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; MICE; MYOBLASTS; OXIDATIVE STRESS; PYRIDINES; PYRROLES; RATS; SELENIUM; SELENOPROTEINS;

EID: 84869869459     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.10.010     Document Type: Article

References (44)

1. Antons K.A., Williams C.D., Baker S.K., Phillips P.S. Clinical perspectives of statin-induced rhabdomyolysis. American Journal of Medicine 2006, 119:400-409.
2. Arbogast S., Beuvin M., Fraysse B., Zhou H., Muntoni F., Ferreiro A. Oxidative stress in SEPN1-related myopathy: from pathophysiology to treatment. Annals of Neurology 2009, 65:677-686.
3. Baker S.K. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle & Nerve 2005, 31:572-580.
4. Bellinger F.P., Raman A.V., Reeves M.A., Berry M.J. Regulation and function of selenoproteins in human disease. Biochemical Journal 2009, 422:11-22.
5. Bogsrud M., Retterstol K., Ose L., Malt U., Woldseth B. The effect of Q10 and selenium supplement on adverse effects in statin treatment. Abstracts of the XV International Symposium on Atherosclerosis 2009.
6. Bouitbir J., Charles A.L., Echaniz-Laguna A., Kindo M., Daussin F., Auwerx J., Piquard F., Geny B., Zoll J. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. European Heart Journal 2012, 33:1397-1407.
7. Caso G., Kelly P., McNurlan M.A., Lawson W.E. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. American Journal of Cardiology 2007, 99:1409-1412.
8. Chariot P., Bignani O. Skeletal muscle disorders associated with selenium deficiency in humans. Muscle & Nerve 2003, 27:662-668.
9. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:39-43.
10. Driscoll D.M., Copeland P.R. Mechanism and regulation of selenoprotein synthesis. Annual Review of Nutrition 2003, 23:17-40.
11. Endo A., Kuroda M., Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Letters 1976, 72:323-326.
12. Grünler J., Ericsson J., Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochimica et Biophysica Acta 1994, 1212:259-277.
13. Hajieva P., Mocko J.B., Moosmann B., Behl C. Novel imine antioxidants at low nanomolar concentrations protect dopaminergic cells from oxidative neurotoxicity. Journal of Neurochemistry 2009, 110:118-132.
14. Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. American Journal of Cardiology 2006, 97:44C-51C.
15. Joy T.R., Hegele R.A. Narrative review: statin-related myopathy. Annals of Internal Medicine 2009, 150:858-868.
16. Kimes B.W., Brandt B.L. Properties of a clonal muscle cell line from rat heart. Experimental Cell Research 1976, 98:367-381.
17. Kromer A., Moosmann B. Statin-induced stalling of selenoprotein synthesis in hepatocytes. Journal of Clinical Pharmacology 2008, 48:S1103.
18. Kromer A., Moosmann B. Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways. Molecular Pharmacology 2009, 75:1421-1429.
19. Lankin V.Z., Tikhaze A.K., Kukharchuk V.V., Konovalova G.G., Pisarenko O.I., Kaminnyi A.I., Shumaev K.B., Belenkov Y.N. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Molecular and Cellular Biochemistry 2003, 249:129-140.
20. Lee S., Shin H.S., Shireman P.K., Vasilaki A., Van Remmen H., Csete M.E. Glutathione-peroxidase-1 null muscle progenitor cells are globally defective. Free Radical Biology and Medicine 2006, 41:1174-1184.
21. Lescure A., Rederstorff M., Krol A., Guicheney P., Allamand V. Selenoprotein function and muscle disease. Biochimica et Biophysica Acta 2009, 1790:1569-1574.
22. Mallinson J.E., Constantin-Teodosiu D., Sidaway J., Westwood F.R., Greenhaff P.L. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. Journal of Physiology 2009, 587:219-230.
23. McGuinness B., Passmore P. Can statins prevent or help treat Alzheimer's disease?. Journal of Alzheimer's Disease 2010, 20:925-933.
24. Moosmann B., Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004, 363:892-894.
25. Moosmann B., Behl C. Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway. Trends in Cardiovascular Medicine 2004, 14:273-281.
26. Moran J.L., Li Y., Hill A.A., Mounts W.M., Miller C.P. Gene expression changes during mouse skeletal myoblast differentiation revealed by transcriptional profiling. Physiological Genomics 2002, 10:103-111.
27. Pella, D., Fedacko, J., Rybar, R., Fedackova, P., Potocekova, D., 2008. Coenzyme Q10 and selenium in statin side effects. Results of randomised double-blind clinical study. Abstracts of the International Medical CoQ10 Congress, Prague, Czech Republic.
28. Phillips P.S., Haas R.H. Statin myopathy as a metabolic muscle disease. Expert Review of Cardiovascular Therapy 2008, 6:971-978.
29. Phillips P.S. Balancing randomized trials with anecdote. Annals of Internal Medicine 2009, 150:885-886.
30. Porta E.A., Monserrat A.J., Berra A., Rubio M.C. Effects of lovastatin and leupeptin on ceroidogenesis of vitamin E-deficient and -supplemented young rats. Advances in Experimental Medicine and Biology 1989, 266:169-188.
31. Rosenbaum, D., Dallongeville, J., Sabouret, P., Bruckert, E., 2012. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutrition, Metabolism and Cardiovascular Diseases, in press. doi:10.1016/j.numecd.2012.04.012.
32. Schoenmakers E., Agostini M., Mitchell C., Schoenmakers N., Papp L., Rajanayagam O., Padidela R., Ceron-Gutierrez L., Doffinger R., Prevosto C., et al. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. Journal of Clinical Investigation 2010, 120:4220-4235.
33. Schomburg L., Dumitrescu A.M., Liao X.H., Bin-Abbas B., Hoeflich J., Köhrle J., Refetoff S. Selenium supplementation fails to correct the selenoprotein synthesis defect in subjects with SBP2 gene mutations. Thyroid 2009, 19:277-281.
34. Sinzinger H., Lupattelli G., Chehne F., Oguogho A., Furberg C.D. Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. Journal of Clinical Pharmacy and Therapeutics 2001, 26:303-310.
35. Sinzinger H., O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. British Journal of Clinical Pharmacology 2004, 57:525-528.
36. Sirvent P., Mercier J., Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Current Opinion in Pharmacology 2008, 8:333-338.
37. Skogastierna C., Johansson M., Parini P., Eriksson M., Eriksson L.C., Ekström L., Björkhem-Bergman L. Statins inhibit expression of thioredoxin reductase 1 in rat and human liver and reduce tumour development. Biochemical and Biophysical Research Communications 2012, 417:1046-1051.
38. Sodha N.R., Boodhwani M., Ramlawi B., Clements R.T., Mieno S., Feng J., Xu S.H., Bianchi C., Sellke F.W. Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia. Journal of Cardiac Surgery 2009, 23:312-320.
39. Stoll L.L., McCormick M.L., Denning G.M., Weintraub N.L. Antioxidant effects of statins. Drugs of Today 2004, 40:975-990.
40. Suzuki T., Kelly V.P., Motohashi H., Nakajima O., Takahashi S., Nishimura S., Yamamoto M. Deletion of the selenocysteine tRNA gene in macrophages and liver results in compensatory gene induction of cytoprotective enzymes by Nrf2. Journal of Biological Chemistry 2008, 283:2021-2030.
41. Tobert J.A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery 2003, 2:517-526.
42. Warner G.J., Berry M.J., Moustafa M.E., Carlson B.A., Hatfield D.L., Faust J.R. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. Journal of Biological Chemistry 2000, 275:28110-28119.
43. Yaffe D., Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977, 270:725-727.
44. Young J.M., Florkowski C.M., Molyneux S.L., McEwan R.G., Frampton C.M., George P.M., Scott R.S. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. American Journal of Cardiology 2007, 100:1400-1403.